491 results on '"Amici, Augusto"'
Search Results
2. Insights into the effect of polyethylene terephthalate (PET) microplastics on HER2 signaling pathways
3. Evaluation of anticancer role of a novel ruthenium(II)-based compound compared with NAMI-A and cisplatin in impairing mitochondrial functionality and promoting oxidative stress in triple negative breast cancer models
4. Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer.
5. Protein corona alleviates adverse biological effects of nanoplastics in breast cancer cells.
6. Acetylshikonin isolated from Lithospermum erythrorhizon roots inhibits dihydrofolate reductase and hampers autochthonous mammary carcinogenesis in Δ16HER2 transgenic mice
7. The intracellular trafficking mechanism of Lipofectamine-based transfection reagents and its implication for gene delivery.
8. In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer
9. Factors Determining the Superior Performance of Lipid/DNA/Protammine Nanoparticles over Lipoplexes
10. The Transformative Potential of Lipid Nanoparticle–Protein Corona for Next-Generation Vaccines and Therapeutics
11. Manipulation of lipoplex concentration at the cell surface boosts transfection efficiency in hard-to-transfect cells
12. Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib
13. Personalized liposome–protein corona in the blood of breast, gastric and pancreatic cancer patients
14. The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells
15. Video 1 from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
16. Supplementary S1 from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
17. Supplementary Tables from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
18. Data from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
19. Data from Stathmin Is Required for Normal Mouse Mammary Gland Development and Δ16HER2-Driven Tumorigenesis
20. Video S1 from Stathmin Is Required for Normal Mouse Mammary Gland Development and Δ16HER2-Driven Tumorigenesis
21. Supplementary Materials and Methods, Figure Legends, Figures 1 - 6, Tables 1 - 2 from Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients
22. Supplementary Data from Stathmin Is Required for Normal Mouse Mammary Gland Development and Δ16HER2-Driven Tumorigenesis
23. Data from Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer
24. Supplementary Tables from Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer
25. Supplementary Figures 1-6, Supplementary Materials and Methods from Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer
26. Supplementary Methods from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
27. Supplementary Figure 7 from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
28. Supplementary Figure 6 from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
29. Supplementary Figure S1 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
30. Data from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
31. Supplementary Figure 8 from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
32. Supplementary Figure 1 from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
33. Supplementary Figure 5 from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
34. Supplementary Figure 1 from Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations
35. Supplementary Figure 5 from Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations
36. Supplementary Figure Legends 1-4, Tables Legends 1-8 from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
37. Supplementary Figures 1-2 from Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity
38. Data from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
39. Supplementary Table 1 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
40. Supplementary Table 1 from Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations
41. Supplementary Figure 2 from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
42. Supplementary Table 2 from Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations
43. Supplementary Tables 1-2, Figures 1-5 from Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations
44. Supplementary Figure 4 from Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations
45. Supplementary Table 4 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
46. Supplementary Table 3 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
47. Data from Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity
48. Supplementary methods, figure legends and references from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
49. Supplementary Figure 3 from A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
50. Data from Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.